15997-89-4 Usage
Description
4,5-Dichlorophthalimide (5,6-dichloro-1H-isoindole-1,3(2H)-dione) is a phthalimide derivative that has been synthesized from 5,6-dichloro-1,3-isobenzofurandione and characterized by 1H, 13C-NMR, and IR. It is known for its dipole moment, polarizability, and first-order hyperpolarizability, which have been investigated using ab initio and density functional theory calculations.
Uses
Used in Pharmaceutical Synthesis:
4,5-Dichlorophthalimide is used as a reactant in the synthesis of various pharmaceutical compounds, such as 5′-N-(4′′,5′′-dichlorophthaloyl)-3′-azido-2′,3′-dideoxythymidine and 2-amino-4,5-dichlorobenzoic acid. It plays a crucial role in the development of new drugs and therapies.
Used in Chemical Research:
4,5-Dichlorophthalimide serves as a reactant in the synthesis of 4,5-dichloro-1,2-benzenedicarboxamide, contributing to the advancement of chemical research and the discovery of new compounds with potential applications.
Used in Catalyst Development:
In the field of catalysis, 4,5-dichlorophthalimide is used as an additive in the Ir-BICP catalyzed asymmetric hydrogenation of 2,3,3-trimethylindolenine to improve enantioselectivity, enhancing the efficiency and selectivity of chemical reactions.
Used in Material Science:
4,5-Dichlorophthalimide is utilized as a reactant in the synthesis of octachloro-Cu-phthalocyanine, a compound with potential applications in material science, such as in the development of new materials with specific properties.
Used in Organic Chemistry:
As a reagent, 4,5-dichlorophthalimide is employed in the synthesis of 7-tert-butylthianthrene-2,3-dicarboxylic imide, contributing to the expansion of organic chemistry and the creation of new organic compounds.
Used in Synthesis of N-(3-bromopropyl)-4,5-dichlorophthalimide:
4,5-Dichlorophthalimide serves as a starting material in the synthesis of N-(3-bromopropyl)-4,5-dichlorophthalimide, which can be used in various chemical applications and reactions.
Used in Phosphine-Catalyzed Allylic Substitution:
4,5-Dichlorophthalimide acts as a nucleophilic partner in the phosphine-catalyzed allylic substitution of Morita-Baylis-Hillman acetates to form N-protected β-amino phosphonic acid esters, a reaction with potential applications in the synthesis of complex organic molecules.
Check Digit Verification of cas no
The CAS Registry Mumber 15997-89-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,5,9,9 and 7 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 15997-89:
(7*1)+(6*5)+(5*9)+(4*9)+(3*7)+(2*8)+(1*9)=164
164 % 10 = 4
So 15997-89-4 is a valid CAS Registry Number.
InChI:InChI=1/C8H3Cl2NO2/c9-5-1-3-4(2-6(5)10)8(13)11-7(3)12/h1-2H,(H,11,12,13)
15997-89-4Relevant articles and documents
ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF
-
Page/Page column 86, (2021/08/13)
Compounds of formula (I) useful as inhibitors of ADAMTS-5 and/or ADAMTS-4, pharmaceutical compositions thereof, and use of them as therapeutic agents for the treatment of diseases involving degradation of cartilage or disruption of cartilage homeostasis, in particular osteoarthrosis and/or rheumatoid arthritis, are disclosed.
Grinding imidation of anhydrides on smectite clays as recyclable and heterogeneous catalysts under solvent-free conditions
Marvi, Omid
, p. 3501 - 3504 (2017/08/14)
Imidation of various anhydrides employing solvent-free grindstone technique using smectite clays as recyclable and green catalysts was examined and obtained excellent yields.
Discovery of novel dual-action antidiabetic agents that inhibit glycogen phosphorylase and activate glucokinase
Zhang, Lei,Chen, Xiaojie,Liu, Jun,Zhu, Qingzhang,Leng, Ying,Luo, Xiaomin,Jiang, Hualiang,Liu, Hong
, p. 624 - 639 (2013/02/21)
Dual-target-directed agents simultaneously inhibiting glycogen phosphorylase (GP) and activating glucokinase (GK) could decelerate the inflow of glucose from glycogenolysis and accelerate the outflow of glucose in the liver, therefore allow for a better control over hyperglycaemia in a synergetic manner. A series of hybrid compounds were designed by structure-assisted and ligand-based strategies. In vitro bioassays found two novel compounds (1j, 6g) worthy of further optimization on balance of dual action to GP and GK. In addition, for single-target activity, two compounds exhibited more potent GP inhibitory activity and four compounds showed better GK activation than their corresponding references.
